References
- Atkinson SA, Shah JK, McGee C, Steele BT. Mineral excretion in premature infants receiving various diuretic therapies. J Pediatr 1988;113:540–5
- Clarke JM, Ramsay LE, Shelton JR, et al. Factors influencing comparative bioavailability of spironolactone tablets. J Pharm Sci 1977;66:1429–32
- Mclnnes GT, Asbury MJ, Ramsay LE, et al. Effect of micronization on the bioavailability and pharmacologic activity of spironolactone. J Clin Pharmacol 1982;22:410–17
- Dong Y, Ng WK, Shen S, et al. Preparation and characterization of spironolactone nanoparticles by antisolvent precipitation. Int J Pharm 2009;375:84–8
- Limayem Blouza I, Charcosset C, Sfar S, Fessi H. Preparation and characterization of spironolactone-loaded nanocapsules for paediatric use. Int J Pharm 2006;325:124–31
- Laouini A, Jaafar-Maalej C, Sfar S, et al. Liposome preparation using a hollow fiber membrane contactor – application to spironolactone encapsulation. Int J Pharm 2011;415:53–61
- Abd Elazeem Soliman O, Kimura K, Hirayama F, et al. Amorphous spironolactone-hydroxypropylated cyclodextrin complexes with superior dissolution and oral bioavailability. Int J Pharm 1997;149:73–83
- Fages J, Lochard H, Letourneau J-J, et al. Particle generation for pharmaceutical applications using supercritical fluid technology. Powder Technol 2004;141:219–26
- Türk M, Bolten D. Formation of submicron poorly water-soluble drugs by rapid expansion of supercritical solution (RESS): results for Naproxen. J Supercritical Fluids 2010;55:778–85
- Liu H, Zhou L, Pan W. Preparation of budesonide-poly (ethylene oxide) solid dispersions using supercritical fluid technology. Drug Dev Ind Pharm 2007;33:959–66
- José Cocero M, Martín A, Mattea F, Varona S. Encapsulation and co-precipitation processes with supercritical fluids: fundamentals and applications. J Supercritical Fluids 2009;47:546–55
- Yoda S, Otake K, Takebayashi Y, et al. Effect of supercritical fluids conditions on the properties of silica--titania aerogels. J Non-Crystalline Solids 2001;285:8–12
- Kinoshita M, Baba K, Nagayasu A, et al. Improvement of solubility and oral bioavailability of a poorly water-soluble drug, TAS-301, by its melt-adsorption on a pourous calcium silicate. J Pharm Sci 2002;91:362–70
- Chino T, Yasuno N, Yanagihara Y, Suzuki H. Solid dispersion of spironolactone with porous silica prepared by the solvent method. Pharmazie 2007;62:599–603
- Sathigari SK, Ober CA, Sanganwar GP, et al. Single-step preparation and deagglomeration of itraconazole microflakes by supercritical antisolvent method for dissolution enhancement. J Pharm Sci 2011;100:2952–65
- Sanganwar GP, Sathigari S, Jayachandra Babu R, Gupta RB. Simultaneous production and co-mixing of microparticles of nevirapine with excipients by supercritical antisolvent method for dissolution enhancement. Eur J Pharm Sci 2010;39:164–74
- Miura H, Kanebako M, Shirai H, et al. Enhancement of dissolution rate and oral absorption of a poorly water-soluble drug, K-832, by adsorption onto porous silica using supercritical carbon dioxide. Eur J Pharm Biopharm 2010;76:215–21
- Jeunesse E, Woehrle F, Schneider M, Lefebvre HP. Effect of spironolactone on diuresis and urine sodium and potassium excretion in healthy dogs. J Vet Cardiol 2007;9:63–8
- Jankowski A, Skorek-Jankowska A, Lamparczyk H. Simultaneous determination of spironolactone and its metabolites in human plasma. J Pharm Biomed 1996;14:1359–65
- Iuliana Sora D, Udrescu Ş, Albu F, et al. Analytical issues in HPLC/MS/MS simultaneous assay of furosemide, spironolactone and canrenone in human plasma samples. J Pharm Biomed 2010;52:734–40